NAPHCON A OTC
Generic Name and Formulations:
Naphazoline HCl 0.025%, pheniramine maleate 0.3%; oph. soln; contains benzalkonium chloride.
Alcon Laboratories, Inc.
Indications for NAPHCON A:
Ocular redness and itching.
Adults and Children:
<6yrs: not recommended. ≥6yrs: 1–2 drops up to 4 times daily.
Avoid prolonged use. Narrow-angle glaucoma. Hypertension. Cardiovascular disease. Urinary hesitancy. Reevaluate if eye pain, irritation, or visual changes worsen or persist beyond 72hrs. Pregnancy. Nursing mothers.
Avoid MAOIs. Remove soft contact lenses when instilling; may re-insert afterwards.
Vasoconstrictor + antihistamine.
Mydriasis, increased IOP, local irritation, sensitization.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy